- Notes on the Contributors
- Methods in Bioethics
- The Way We Reason Now: Reflective Equilibrium in Bioethics
- Mental Disorder, Moral Agency, and the Self
- ‘Reinventing’ the Rule of Double Effect
- Policy‐Making in Pluralistic Societies
- Tiers Without Tears: the Ethics of a Two‐Tier Health Care System
- Justice and the Elderly
- Organ Transplantation
- For Dignity or Money: Feminists on the Commodification of Women's Reproductive Labour
- The Definition of Death
- The Aging Society and the Expansion of Senility: Biotechnological and Treatment Goals
- Death is a Punch in the Jaw: Life‐Extension and its Discontents
- Precedent Autonomy, Advance Directives, and End‐of‐Life Care
- Physician‐Assisted Death: the State of the Debate
- Abortion Revisited
- Moral Status, Moral Value, and Human Embryos: Implications for Stem Cell Research
- Therapeutic Cloning: Politics and Policy
- Population Genetic Research and Screening: Conceptual and Ethical Issues
- Genetic Interventions and The Ethics of Enhancement of Human Beings
- Pharmacogenomics: Ethical and Regulatory Issues
- Clinical Equipoise: Foundational Requirement or Fundamental Error?
- Research on Cognitively Impaired Adults
- Research in Developing Countries
- Animal Experimentation
- The Implications of Public Health for Bioethics
- Global Health
- Bioethics and Bioterrorism
Abstract and Keywords
While acknowledging the potential benefits of pharmacogenomics as a methodology, a number of comprehensive reports in the past several years examine a multitude of ethical, legal, and social factors that may limit the extent to which these benefits are realized — and realized in ethically acceptable ways. This article aims to identify and explore the most basic ethical and regulatory issues that are likely to arise if pharmacogenomics becomes widely enough used to have a significant impact on research and clinical practice. First, however, it addresses the question of whether pharmacogenomic tests are unique when compared to other genetic tests and thus deserving of more or less stringent ethical and regulatory requirements.
Matthew DeCamp entered the Duke University Medical Scientist Training Program (MD/Ph.D.) in 2000 and is currently pursuing graduate work in the Department of Philosophy. His current research focuses on the relationship between intellectual property rules and global distributive justice in global health.
Allen Buchanan is James B. Duke Professor of Philosophy and Professor of Law at Duke University, where he is also an Investigator at the Institute of Genome Sciences and Policy. Buchanan's work is mainly in Bioethics and in Political Philosophy. His most recent books are From Chance to Choice: Genetics and Justice (co‐authored with Dan W. Brock, Norman Daniels, and Daniel Wikler; Cambridge University Press, 2000) and Justice, Legitimacy, and Self‐Determination: Moral Foundations for International Law (Oxford University Press, 2003).